The latest news from ASH 2024 focused on mantle cell lymphoma (MCL) including abstracts, features, and helpful conference information.
According to data from the 66th ASH Annual Meeting, advancements in the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL) have introduced novel therapies such as BTK inhibitors.
While the findings affirm ibrutinib’s role in improving outcomes for patients from Brazil with CLL, they underscore the challenges of managing toxicities and late-line therapy.
Will you be attending “A Shifting Landscape: Treatment of MCL” on Monday, December 9 at ASH?
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
